Merck, also known as MSD outside of the United States and Canada, has achieved priority review status from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) concerning sotatercept. This innovative activin signaling inhibitor is under evaluation for the treatment of pulmonary arterial hypertension (PAH) in adult patients, a rare and life-threatening condition characterized by the narrowing of lung blood vessels, leading to strain on the heart.
The FDA has designated a target action date of March 26, 2024. The application draws from promising outcomes in Phase 3 STELLAR trial, where the sotatercept displayed significant enhancements across various parameters, offering a potential new avenue for addressing this challenging disease. If approved, sotatercept would represent a groundbreaking treatment for PAH, as it would be the first of its kind in this category.
PAH is a rare, progressive condition with a five-year mortality rate of approximately 43%, significantly impacting patients’ quality of life and longevity. Merck’s innovative approach offers hope for improving outcomes in this patient population.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
